Endocrine Abstracts

Bisphosphonates, because of their efficacy, safety and ease of administration, are accepted as first-line therapy for osteoporosis worldwide. They decrease the rate of bone resorption but have also distinct pharmacological properties including preferential uptake in the skeleton, primarily at sites with increased bone remodeling, and long-term retention in bone. There are differences among bisphosphonates both in their affinity for bone as well as in their antiresorptive poten...

Introduction: Fibroblast growth factor 23 (FGF23) and PTH have been identified as major players in the bone-parathyroid-kidney axis controlling phosphate homeostasis. In patients with primary hyperparathyroidism (PHPT) data on the relationship between PTH and FGF23 are scarce and not always concordant.Objective: The aim of our study was to evaluate whether the relationship between PTH and FGF23 was altered in patients with primary hyperparathyroidism and...